Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2007 Jan 23;21(1):14–23. doi: 10.1002/jcla.20158

Chylomicron accelerates C3 tick‐over by regulating the role of Factor H, leading to overproduction of acylation stimulating protein

Takayuki Fujita 1,✉, Takayuki Fujioka 1, Tetsuo Murakami 2, Atsushi Satomura 1, Yoshinobu Fuke 1, Koichi Matsumoto 1
PMCID: PMC6649021  PMID: 17245758

Abstract

Acylation stimulating protein (ASP) is a fragment of the third component of complement (C3) that is generated in the presence of chylomicron, and plays a role in the synthesis of triacylglycerol by transporting free fatty acids into adipocytes. However, the precise mechanism of ASP generation, especially the role of chylomicron in ASP generation, is unknown. We examined the mechanism through which chylomicron induces ASP generation. Ultracentrifugationally separated chylomicron was incubated with normal human serum (NHS) under various conditions, and the amounts of complement activation products and ASP in the incubation mixture were determined by enzyme‐linked immunosorbent assay (ELISA). Upon incubation of NHS with various amounts of chylomicron for 120 min, ASP was generated in a dose‐dependent manner. The time course of the production of ASP was similar to the time course of the C3 tick‐over phenomenon that occurred by depletion of factor H from the serum. The complement activation induced by chylomicron was different from the usual complement activation that occurs under the regulation of factor H and factor I with respect to the time course and the amount of ASP produced. Our results indicate that chylomicron accelerates C3 tick‐over by regulating the role of factor H, leading to the overproduction of ASP. J. Clin. Lab. Anal. 21:14–23, 2007. © 2007 Wiley‐Liss, Inc.

Keywords: acylation stimulating protein, C3 tick‐over, complement activation, chylomicron, adipocyte, factor H

REFERENCES

  • 1. Mohamed‐Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998;22:1145–1158. [DOI] [PubMed] [Google Scholar]
  • 2. Caro JF, Sinha MK, Kolaczynski MK, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes 1996;45:1455–1462. [DOI] [PubMed] [Google Scholar]
  • 3. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor‐alpha: direct role in obesity‐linked insulin resistance. Science 1993;259:87–91. [DOI] [PubMed] [Google Scholar]
  • 4. Mohamed‐Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin‐6, but not tumor necrosis factor‐α, in vivo. J Clin Endocrinol Metab 1997;82:4196–4200. [DOI] [PubMed] [Google Scholar]
  • 5. Ailhaud G, Grimaldi P, Negrel R. Cellular and molecular aspect adipose tissue development. Annu Rev Nutr 1992; 56:731–773. [DOI] [PubMed] [Google Scholar]
  • 6. Chen NX, Hausman GJ, Wright JT. Influence of thyroxine in vivo on preadipocyte development and insulin‐like growth factor‐1 and IGF binding protein secretion in fetal stromal vascular cell cultures. Obes Res 1996;4:357–366. [DOI] [PubMed] [Google Scholar]
  • 7. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen‐like factor, apMI(AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286–289. [DOI] [PubMed] [Google Scholar]
  • 8. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312. [DOI] [PubMed] [Google Scholar]
  • 9. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992;267: 12736–12741. [PubMed] [Google Scholar]
  • 10. White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 1992;267:9210–9213. [PubMed] [Google Scholar]
  • 11. Lesavre PH, Hugli TE, Esser AF, Müller‐Eberhard HJ. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol 1979;123:529–534. [PubMed] [Google Scholar]
  • 12. Schreiber RD, Pangburn MK, Lesavre PH, Müller‐Eberhard HJ. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci USA 1978; 75:3948–3952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Pangburn MK, Schreiber RD, Müller‐Eberhard HJ. Human complement C3b inactivator: isolation, characterization and demonstration of an absolute requirement for the serum protein b1H for cleavage of C3b and C4b in solution. J Exp Med 1977;146:257–270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Bokisch VA, Müller‐Eberhard HJ. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 1970;49:2427–2436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Cianflone KM, Sniderman AD, Walsh MJ, Vu HT, Gagnon J, Rodriguez MA. Purification and characterization of acylation stimulating protein. J Biol Chem 1989;264:426–430. [PubMed] [Google Scholar]
  • 16. Yasruel Z, Cianflone K, Sniderman AD, Rosenbloom M, Rodriguez MA. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids 1991;26:495–499. [DOI] [PubMed] [Google Scholar]
  • 17. Zhunan X, Cianflone K. Acylation‐stimulating protein precursor proteins in adipose tissue in human obesity. Metabolism 2003;52:1360–1366. [DOI] [PubMed] [Google Scholar]
  • 18. Morimoto Y, Taniguchi H, Yamashiro Y, Ejiri K, Baba S, Arimoto Y. Complements in diabetes mellitus: activation of complement system evidenced by C3d elevation in IDDM. Diabetes Res Clin Pract 1988;5:309–312. [DOI] [PubMed] [Google Scholar]
  • 19. Mantov S, Raev D. Addictive effect of diabetic and systemic hypertension on the immune mechanisms of atherosclerosis. Int J Cardiol 1996;56:145–148. [DOI] [PubMed] [Google Scholar]
  • 20. Muscari A, Massarelli G, Bastagli L, et al. Relationship of serum C3 to fasting insulin risk factors and previous ischemic events in middle‐aged men. Eur Heart J 2000;21:1081–1090. [DOI] [PubMed] [Google Scholar]
  • 21. Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000;23:779–785. [DOI] [PubMed] [Google Scholar]
  • 22. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP. Effect of body weight and calory restriction on serum complement proteins, including factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol 1997; 108:507–515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Sissons JG, West RJ, Fallows J, et al. The complement abnormalities of lipodystrophy. N Engl J Med 1976;294:461–465. [DOI] [PubMed] [Google Scholar]
  • 24. Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M, Ohi H. Inhibitory effect of free sialic acid on complement activation and its significance in hypocomplementemic glomerulonephritis. J Clin Lab Anal 1999;13:173–179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Scantlebury T, Maslowska M, Cianflone K. Chylomicron‐specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes. J Biol Chem 1998;273:20903–20909. [DOI] [PubMed] [Google Scholar]
  • 26. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation‐stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594–1602. [DOI] [PubMed] [Google Scholar]
  • 27. Xia Z, Stanhope KL, Digitale E, et al. Acylation‐stimulating protein (ASP)/complement C3adesArg deficiency results in increased energy expenditure in mice. J Biol Chem 2004;279: 4051–4057. [DOI] [PubMed] [Google Scholar]
  • 28. Matsushita M, Fujita T. Activation of the classic complement pathway by mannose‐binding protein in association with a novel C1s‐like serine protease. J Exp Med 1992;176:1497–1502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Satomura A, Endo M, Ohi H, et al. Significant elevations in serum mannose‐binding lectin levels in patients with chronic renal failure. Nephron 2002;92:702–704. [DOI] [PubMed] [Google Scholar]
  • 30. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345–1353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation. Clin Chem 1999;45:1190–1199. [PubMed] [Google Scholar]
  • 32. Tamerius JD, Pangburn MK, Müller‐Eberhard HJ. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody. J Immunol 1985;135:2015–2019. [PubMed] [Google Scholar]
  • 33. Kolb WP, Morrow PR, Tamerius JD. Ba and Bb fragments of factor B activation: Fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm 1989;6:175–204. [DOI] [PubMed] [Google Scholar]
  • 34. Pangburn MK, Schreiber RD, Müller‐Eberhard HJ. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 1981;154:856–867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Pangburn MK, Müller‐Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway: acquisition of C3b‐like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 1980;152:1102–1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Hack CE, Paardekooper J, van Milligen F. Demonstration in human plasma of a form of C3 that has the conformation of “C3b‐like C3.” J Immunol 1990;144:4249–4255. [PubMed] [Google Scholar]
  • 37. Gadjeva M, Dodds AW, Taniguchi‐Sidle A, Willis AC, Isenman DE, Law SKA. The covalent binding reaction of complement component C3. J Immunol 1998;161:985–990. [PubMed] [Google Scholar]
  • 38. Müller‐Eberhard HJ, Götze O. C3 proactivator convertase and its mode of action. J Exp Med 1972;135:1003–1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. Extensive deposits of complement C3d and C5b‐9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 2002;43:1104–1108. [PubMed] [Google Scholar]
  • 40. Manderson AP, Pickering MC, Botto M, Walport MJ, Parish CR. Continual low‐level activation of the classic complement pathway. J Exp Med 2001;194:747–756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002;31: 424–428. [DOI] [PubMed] [Google Scholar]
  • 42. Tamano M, Fuke Y, Endo M, Ohsawa I, Fujita T, Ohi H. Urinary complement factor H in renal disease. Nephron 2002;92:705–707. [DOI] [PubMed] [Google Scholar]
  • 43. Hugh P, Barrett R. Kinetics of triglyceride rich lipoproteins: chylomicrons and very low density lipoproteins. Atherosclerosis 1998;141:S35–S40. [DOI] [PubMed] [Google Scholar]
  • 44. Hasselbacher P, Hahn JL. Activation of the alternative pathway of complement by microcrystalline cholesterol. Atherosclerosis 1980;37:239–245. [DOI] [PubMed] [Google Scholar]
  • 45. Weintraub MS. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III and type IV hyperlipoproteinemic individuals: effect of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987;79:1110–1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. van Greevenbroek MMJ, de Bruin TWA. Chylomicron synthesis by intestinal cells in vitro and in vivo. Atherosclerosis 1998; 141:S9–S16. [DOI] [PubMed] [Google Scholar]
  • 47. Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial complement 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002;22:811–816. [DOI] [PubMed] [Google Scholar]
  • 48. Gu JW, Wang J, Stockton A, Lokitz B, Henegar L, Hall JE. Cytokine gene expression profiles in kidney medulla and cortex of obese hypertensive dogs. Kidney Int 2004;66:713–721. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES